Product Information

GABAPENTIN ER 300 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.6227 per EA under NDC 68382060816. Its NADAC has been published 122 times since Jul 17, 2024.

FDA first approved this application on Jan 24, 2024. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

GABAPENTIN ER 300 MG TABLET

gabapentin
$0.6227per EA
High Outlier

Strength

300 mg/1

NDC

68382060816

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

GABAPENTIN

Approval Type

Generic (ANDA)

FDA Application

ANDA203934

FDA Approved

1/24/2024

TE Code

AB2

On Market Since

1/25/2024

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for GABAPENTIN ER 300 MG TABLET has been published 122 times since Jul 17, 2024, and over the history we have for it it has declined 62.1%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6227 per EA
All-time high$2.2901 (Jun 11, 2025)
All-time low$0.6227 (Oct 21, 2026)
52-week high$1.4921
52-week low$0.6227
Median price$1.5084
Average price$1.5714
Largest weekly change+35.5% (Aug 21, 2024)
Weeks tracked122
Tracking sinceJul 17, 2024

Price History

1W

0.0%

1M

-2.5%

3M

-25.3%

6M

-55.5%

1Y

-61.0%

3Y

N/A

5Y

N/A

All

-62.1%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of GABAPENTIN ER 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN ER 300 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.6227 per EA (NDC 68382060816), effective Nov 11, 2026.

How has the price of GABAPENTIN ER 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for GABAPENTIN ER 300 MG TABLET has declined 62.1%. It has been tracked across 122 weekly CMS publications since Jul 17, 2024.

What are the highest and lowest recorded NADAC prices for GABAPENTIN ER 300 MG TABLET?

Since Jul 17, 2024, the NADAC for GABAPENTIN ER 300 MG TABLET has ranged from a low of $0.6227 (Oct 21, 2026) to a high of $2.2901 (Jun 11, 2025), with a median of $1.5084 per EA.

Are there cheaper alternatives to GABAPENTIN ER 300 MG TABLET?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GABAPENTIN ER 300 MG TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures GABAPENTIN ER 300 MG TABLET?

GABAPENTIN ER 300 MG TABLET (NDC 68382060816) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.